Literature DB >> 1905549

Diagnostic usefulness of cerebrospinal fluid in multiple sclerosis.

P D Mehta1.   

Abstract

Multiple sclerosis (MS) is one of the most common demyelinating diseases of the central nervous system affecting adults between the ages of 20 and 40 years. Clinically, it is characterized by episodes of exacerbations and remissions. Although the cause of MS is unknown, it is generally believed that one or more infectious agents triggers an autoimmune response that causes myelin destruction. There is no known cure for this disease; however, early diagnosis is helpful in the management of patients with MS. The diagnosis of MS is commonly made on the basis of established clinical criteria. No specific laboratory diagnostic test exists, but detection of abnormalities in cerebrospinal fluid (CSF) is a useful aid to support the clinical diagnosis of MS. This review describes the most common CSF abnormalities. These include (a) elevation of immunoglobulin G (IgG), IgG index and IgG synthesis rate; and (b) detection of oligoclonal IgG bands in the CSF by electrophoresis and isoelectric-focusing procedures.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905549     DOI: 10.3109/10408369109106864

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  3 in total

1.  Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis.

Authors:  K H Rand; H Houck; N D Denslow; K M Heilman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

Review 2.  Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway.

Authors:  Ariel D Stock; Jing Wen; Chaim Putterman
Journal:  Front Immunol       Date:  2013-12-25       Impact factor: 7.561

3.  Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis.

Authors:  Krista D DiSano; Darlene B Royce; Francesca Gilli; Andrew R Pachner
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.